The bolt-on deal gives Merck access to a series of preclinical-stage TRPML1 agonists which Calporta is developing as treatments for various lysosomal storage and neurodegenerative disorders ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback